Acorda Therapeutics, Inc.
) continues to work on expanding the label of its lead product,
Ampyra (dalfampridine-ER). Ampyra is currently approved for the
improvement of walking in multiple sclerosis patients. It is
available outside the U.S. under the trade name Fampyra. Acorda
has a license and collaboration agreement with
) for the development and commercialization of Fampyra outside
Ampyra is being studied for other indications as well
including cerebral palsy (encouraging efficacy data presented
from a phase II proof-of-concept study) and post-stroke
Earlier this week, Acorda presented phase II data on the
post-stroke deficits indication at the annual meeting of the
American Neurological Association. Results from the
proof-of-concept study showed that Ampyra was well-tolerated and
improved walking as measured by the Timed 25-Foot Walk test
(T25FW). Top-line data from this study had been released earlier
this year in April.
The study was mainly conducted to evaluate the safety and
tolerability of Ampyra - other efficacy measures were also
studied. Acorda intends to commence a phase IIb/III study for the
post-stroke deficits indication potentially in the second quarter
Acorda currently carries a Zacks Rank #4 (Sell). We remain
concerned about the company's dependence on Ampyra for growth.
The company's pipeline, while interesting, is primarily
early-stage in nature apart from diazepam nasal spray. Most
candidates are quite a few years away from hitting the
At present, companies like
) look attractive. Both are Zacks Rank #1 (Strong Buy) stocks.
ACORDA THERAPT (ACOR): Free Stock Analysis
ALEXION PHARMA (ALXN): Free Stock Analysis
BIOGEN IDEC INC (BIIB): Free Stock Analysis
ISIS PHARMACEUT (ISIS): Free Stock Analysis
To read this article on Zacks.com click here.